Characteristics of patients enrolled
No. | 19 |
| Sex, F/M | 12/7 |
| Median age, y (range) | 36 (26-52) |
| Disease course | |
| SPMS | 15 |
| RRMS | 4 |
| Median age at disease onset, y (range) | 24 (15-46) |
| Median disease duration, y (range) | 12 (4-19) |
| Median duration of progressive phase, y (range) | 5 (1-11) |
| Previous treatments | |
| Interferon-β | 12 |
| Steroids, azathioprine | 7 |
| Cyclophosphamide | 2 |
| Mitoxantrone | 1 |
No. | 19 |
| Sex, F/M | 12/7 |
| Median age, y (range) | 36 (26-52) |
| Disease course | |
| SPMS | 15 |
| RRMS | 4 |
| Median age at disease onset, y (range) | 24 (15-46) |
| Median disease duration, y (range) | 12 (4-19) |
| Median duration of progressive phase, y (range) | 5 (1-11) |
| Previous treatments | |
| Interferon-β | 12 |
| Steroids, azathioprine | 7 |
| Cyclophosphamide | 2 |
| Mitoxantrone | 1 |
SPMS indicates secondary progressive MS; RRMS, relapsing-remitting MS.